Inhalation CDMO Market Report 2026

Inhalation CDMO Market Overview

• Inhalation CDMO market size has reached to $2.2 billion in 2025 • Expected to grow to $3.03 billion in 2030 at a compound annual growth rate (CAGR) of 6.6% • Growth Driver: Rising Respiratory Disorders Fueling Growth In Inhalation CDMO Market • Market Trend: Strategic Collaborations Transforming Inhalation CDMO Landscape • North America was the largest region in 2025.

What Is Covered Under Inhalation CDMO Market?

An inhalation contract development and manufacturing organization (CDMO) is a specialized organization that provides comprehensive services to pharmaceutical and biotechnology firms for the development and manufacturing of inhalable drugs. These organizations offer a range of services tailored specifically to the needs of inhalation products, including formulation development, analytical testing, process optimization, scale-up, and commercial manufacturing. The main types of products in inhalation CDMO are dry powder inhalers (DPIs), metered dose inhalers (MDIs), nebulizers, and soft mist inhalers. Dry powder inhalers (DPIs) are devices used to deliver medication to the lungs in the form of a dry powder. These are used for different disease indications, such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, acute respiratory distress syndrome, and pulmonary fibrosis, and they are divided by technology, including manual inhalers (SMI) and digital inhalers, and end users are big pharmaceutical companies, small and medium-sized pharmaceutical companies, generic pharmaceutical companies and others.

What Is The Inhalation CDMO Market Growth Forecast?

The inhalation cdmo market size is expected to see strong growth in the next few years. It will grow to $3.03 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to expansion of digital and smart inhalers, growth in personalized medicine and precision therapy, increased investment in inhalation cdmo infrastructure, rising adoption of advanced manufacturing technologies, increasing collaborations between biotech firms and cdmos. Major trends in the forecast period include personalized inhalation therapy development, advanced formulation and drug delivery techniques, regulatory compliance and quality assurance enhancements, contract manufacturing expansion for small and medium-sized firms, integration of smart inhalers and digital health monitoring.

Global Inhalation CDMO Market Segmentation

1) By Product: Dry Powder Inhaler (DPIs), Metered Dose Inhaler (MDIs), Nebulizer, Soft Mist Inhaler 2) By Disease Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Acute Respiratory Distress Syndrome, Pulmonary Fibrosis 3) By Technology: Manual Inhalers (SMI), Digital Inhalers 4) By End-User: Big Pharmaceutical Companies, Small and Medium-sized Pharmaceutical Companies, Generic Pharmaceutical Companies, Other End-Users Subsegments: 1) By Dry Powder Inhaler (DPIs): Capsule-Based DPIs, Diskus-Style DPIs, Multi-Dose DPIs, Unit-Dose DPIs 2) By Metered Dose Inhaler (MDIs): Pressurized MDIs (pMDIs), Breath-Actuated MDIs, Soft Mist MDIs 3) By Nebulizer: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers, Portable Nebulizers 4) By Soft Mist Inhaler: Respimat Inhalers, Other Soft Mist Inhalation Devices

What Is The Driver Of The Inhalation CDMO Market?

The increasing prevalence of respiratory disorders is expected to propel the growth of the inhalation CDMO market going forward. Respiratory disorders are a group of medical conditions that affect the respiratory system, which includes the organs and structures involved in breathing. Inhalation CDMOs are used in the development and manufacturing of products for respiratory disorders due to their expertise in formulating and delivering drugs to the lungs, offering specialized expertise, infrastructure, and resources to pharmaceutical companies seeking to bring innovative inhalation therapies. For instance, in December 2023, according to the National Library of Medicine, a US-based medical library, the global number of chronic obstructive pulmonary disease (COPD) cases among those 25 and older is projected to rise by 23% by 2050, reaching nearly 600 million. Therefore, the increasing prevalence of respiratory disorders is driving the growth of the inhalation CDMO industry.

Key Players In The Global Inhalation CDMO Market

Major companies operating in the inhalation cdmo market are Baxter’s BioPharma Solutions, Lonza Group AG, Catalent Inc., Siegfried Holding AG, Recipharm AB, Stevanato Group SpA, CordenPharma, Nemera, Hovione FarmaCiencia SA, Vectura Group Ltd., CARBOGEN AMCIS, Kindeva Drug Delivery Ltd., Frontage Laboratories Inc, Sanner GmbH, H&T Presspart Ltd., Astech Projects Ltd, Cliantha Research, Copley Scientific, Cambrex Corporation, AptarGroup Inc.

Global Inhalation CDMO Market Trends and Insights

Major companies operating in the inhalation CDMO industry are adopting a strategic partnership approach to provide specialized drug development and delivery. A strategic partnership is a long-term, mutually beneficial arrangement between two or more companies that work together to achieve shared goals. For instance, in May 2023, Hovione, a Portugal-based Contract Development and Manufacturing Organization, partnered with H&T Presspart, a UK-based manufacturer of high-precision metal and plastic components for the pharmaceutical industry, to develop Presspart's Sunrise Capsule-based Dry Powder Inhaler platform. This partnership focuses on developing new technologies that can deliver higher doses of drugs and improve the efficiency of drug delivery to the lungs.

What Are Latest Mergers And Acquisitions In The Inhalation CDMO Market?

In January 2025, Molex Inc., a US-based medical technology company, acquired Vectura Group Ltd. for an undisclosed amount. With this acquisition, Molex aims to significantly expand its inhalation drug delivery and development footprint by integrating Vectura’s deep expertise in formulation, device design, and combination product manufacturing. Vectura Group is a UK-based medical company that specializes in manufacturing inhalation drugs.

Regional Insights

North America was the largest region in the inhalation contract development and manufacturing organization (CDMO) market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Inhalation CDMO Market?

The inhalation contract development and manufacturing organization (CDMO) market includes revenues earned by providing services such as formulation development, analytical testing, device compatibility testing, process development and optimization, scale-up, and manufacturing. The market value includes the value of related goods sold by the service provider or included within the service offering. The inhalation contract development and manufacturing organization (CDMO) market also includes sales of metered-dose inhalers, dry powder inhalers, and inhalation suspension products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Inhalation CDMO Market Report 2026?

The inhalation cdmo market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the inhalation cdmo industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.